Free shipping on all orders over $ 500

Farletuzumab ecteribulin

Cat. No. M25118

All AbMole products are for research use only, cannot be used for human consumption.

Farletuzumab ecteribulin Structure
Synonym:

MORAb-202

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Quality Control & Documentation
Biological Activity

Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a drug-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

Chemical Information
Molecular Weight 149000
CAS Number 2407465-18-1
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Toshio Shimizu, et al. Clin Cancer Res. First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drυg Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors

[2] Mariana Scaranti, et al. Nat Rev Clin Oncol. Exploiting the folate receptor α in oncology

[3] Xin Cheng, et al. Mol Cancer Ther. MORAb-202, an Antibody-Drυg Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

[4] Seiya Sato, et al. Onco Targets Ther. Profile of farletuzumab and its potential in the treatment of solid tumors

[5] Anish Thomas, et al. Lung Cancer. Farletuzumab in lung cancer

Related Drug-Linker Conjugates for ADC Products
MC-SN38 

MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC).
DM4-SMCC 

DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker.
Lys-SMCC-DM1

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization.
Doxorubicin-SMCC 

Doxorubicin-SMCC is a agent-linker conjugate for ADC.
Mal-PEG4-VC-PAB-DMEA-PNU-159682 

Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682.
  Catalog
Abmole Inhibitor Catalog




Keywords: Farletuzumab ecteribulin, MORAb-202 supplier, Drug-Linker Conjugates for ADC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.